Personalized therapy with CFTR modulators: Response of p.Ile148Asn variant
Journal of Cystic Fibrosis · 2025-05 · 24 (3) · 542-547
DOI: 10.1016/j.jcf.2025.01.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025-05. Verfasst von Cláudia S Rodrigues und 5 weiteren Autor:innen. Beteiligte Einrichtung: BioISI-Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Horizon 2020 Framework Programme, Cystic Fibrosis Research Foundation.
Abstract (Originalsprache)
BACKGROUND: Elucidating the molecular and cellular effects caused by CFTR variants is crucial to understand Cystic Fibrosis (CF) disease pathophysiology, but also to predict disease severity, to provide genetic counselling, and to determine the most adequate therapeutic strategy for people with CF (pwCF). While the current CFTR modulator drugs (CFTRm) are approved mainly for pwCF with the most prevalent variant, p.Phe508del, pwCF carrying rare and/or uncharacterized CFTR variants are not eligible. However, previous studies have shown that such rare variants can be rescued by the approved CFTRm, suggesting clinical benefit for those pwCF. Here, we characterized the rare and non-eligible p.Ile148Asn CFTR variant found in Portuguese pwCF, regarding CFTR processing, traffic and function, and response to existing CFTRm. METHODS: We used the forskolin-induced swelling (FIS) assay in intestinal organoids (IOs) from 2 CF individuals carrying p.Ile148Asn in heterozygosity with p.Phe508del and p.Gly542Ter, respectively. Additionally, a Cystic Fibrosis Bronchial Epithelial (CFBE) cell line expressing p.Ile148Asn-CFTR was generated to study the molecular defect of this variant individually. RESULTS: Our results show that p.Ile148Asn is a CF-causing variant, impairing both CFTR plasma membrane (PM) traffic and function, albeit partially. Moreover, p.Ile148Asn-CFTR can be rescued by approved CFTRm in CFBE cells and IOs, suggesting potential clinical benefit for these individuals. CONCLUSION: The work emphasizes the importance of testing CFTRm for rare variants not included in the drug label. It also shows that the 'theranostic' approach using IOs from pwCF, which captures the genetic background of each individual, complements theratyping in cell lines that focuses only on CFTR variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BioISI-Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal.
- BioISI-Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal. Electronic address: ipankonien@fc.ul.pt.
- BioISI-Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal. Electronic address: mdamaral@fc.ul.pt.
Förderung
- Horizon 2020 Framework Programme
- Cystic Fibrosis Research Foundation
Zitieren
APA
Rodrigues, C. S., Railean, V., Ramalho, S. S., Farinha, C. M., Pankonien, I., & Amaral, M. D. (2025). Personalized therapy with CFTR modulators: Response of p.Ile148Asn variant. Journal of Cystic Fibrosis, 24(3), 542-547. https://doi.org/10.1016/j.jcf.2025.01.015
Vancouver
Rodrigues CS, Railean V, Ramalho SS, Farinha CM, Pankonien I, Amaral MD. Personalized therapy with CFTR modulators: Response of p.Ile148Asn variant. Journal of Cystic Fibrosis. 2025;24(3):542-547. doi:10.1016/j.jcf.2025.01.015
BibTeX
@article{Rodrigues2025,
author = {Rodrigues, Cláudia S and Railean, Violeta and Ramalho, Sofia S and Farinha, Carlos M and Pankonien, Ines and Amaral, Margarida D},
title = {Personalized therapy with CFTR modulators: Response of p.Ile148Asn variant},
journal = {Journal of Cystic Fibrosis},
year = {2025},
volume = {24},
number = {3},
pages = {542--547},
doi = {10.1016/j.jcf.2025.01.015}
}
EUVIMED